Webinar May 25th METHYLPHENIDATE FOR CHILDREN AND ADOLESCENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

Slides:



Advertisements
Similar presentations
Attention deficit hyperactivity disorder Implementing NICE guidance 2008 NICE clinical guideline 72.
Advertisements

A Comparison of Early Versus Late Initiation of Renal Replacement Therapy in Critically III Patients with Acute Kidney Injury: A Systematic Review and.
Does the use of antipyretics in children prolong febrile illness? David King Clinical Research Fellow 05/09/2013.
Journal Club Usha Niranjan PICU. Rationale 2 x cases of severe dehydration with metabolic acidosis –requesting for HDU management –as given 40mls/kg fluid.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Pharmacologic Treatment of Pediatric Headaches El-Chammas K, Keyes J, Thompson N,
Summarising findings about the likely impacts of options Judgements about the quality of evidence Preparing summary of findings tables Plain language summaries.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Oxygen Saturation Target Range for Extremely Preterm Infants Manja V, Lakshminrusimha.
Examples of systematic reviews Goran Poropat. Cochrane systematic reviews To make unmanageable amounts of information – manageable Identify, appraise.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2014.
Visit our websites: PhD Study: Evaluation of the Efficacy of the Incredible.
St John’s wort for major depression (Review) Linde, Berner & Kriston (2008/9)
1.A 33 year old female patient admitted to the ICU with confirmed pulmonary embolism. It was noted that she had elevated serum troponin level. Does this.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.
Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2014.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2010.
How to use Clinical Evidence to inform clinical decision making A case presentation using the CE review on acne.
Gut-directed hypnotherapy for functional abdominal pain or irritable bowel syndrome in children: a systematic review Journal club presentation
Cordotomy in mesothelioma- related pain: a systematic review CASP Analysis Emma Lowe.
Enhanced recovery meta-analysis Kirsty Cattle Research Registrar.
Felix I. Zemel, MPH DrPH Student Tufts University School of Medicine.
Dr.Zhila Abedi Asl MD.Fellowship of lnfertility Tehran medical university.
Copyright restrictions may apply A Randomized Trial of Nebulized 3% Hypertonic Saline With Epinephrine in the Treatment of Acute Bronchiolitis in the Emergency.
Critical appraisal Systematic Review กิตติพันธุ์ ฤกษ์เกษม ภาควิชาศัลยศาสตร์ มหาวิทยาลัยเชียงใหม่
Are the results valid? Was the validity of the included studies appraised?
Hypothermia for Neonatal Hypoxic Ischemic Encephalopathy: An Updated Systematic Review and Meta-analysis Tagin MA, Woolcott CG, Vincer MJ, Whyte RK, Stinson.
EBD for Dental Staff Seminar 2: Core Critical Appraisal Dominic Hurst evidenced.qm.
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
Sarah Struthers, MD March 19, 2015
CAT 2: Therapy Maribeth Chitkara, MD Rachel Boykan, MD Stony Brook Long Island Children’s Hospital.
Journal Club Usha Niranjan SPR Paediatrics/ Diabetes & Endocrine.
Do we understand our data? Evaluating comprehension and usefulness of statistical methods for continuous outcomes in meta-analyses Furqaan Sadiq 1, Reem.
Acute Bacterial Rhinosinusitis. Brief Background Typically follows viral infection Dx is by clinical manifestations Streptococcus pneumoniae, Haemophilus.
Treatment for Adolescents With Depression Study (TADS)
Effects of Pediatric Asthma Education on Hospitalizations and Emergency Department Visits: A Meta-Analysis June 3, 2007 Janet M. Coffman, PhD, Michael.
Systematic Reviews.
How to Analyze Systematic Reviews: practical session Akbar Soltani.MD. Tehran University of Medical Sciences (TUMS) Shariati Hospital
Plymouth Health Community NICE Guidance Implementation Group Workshop Two: Debriding agents and specialist wound care clinics. Pressure ulcer risk assessment.
Antidepressants and Suicide Risk in Children and Adolescents: Weighing the Evidence Jill A. Morris, PA-S.
Lenalidomide Maintenance Therapy in Multiple Myeloma: A Meta-Analysis of Randomized Trials Singh PP et al. Proc ASH 2013;Abstract 407.
EBM Conference (Day 2). Funding Bias “He who pays, Calls the Tune” Some Facts (& Myths) Is industry research more likely to be published No Is industry.
CAT 5: How to Read an Article about a Systematic Review Maribeth Chitkara, MD Rachel Boykan, MD.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December 2012.
Copyright © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 18 Systematic Review and Meta-Analysis.
Practice Key Driver Diagram. Chapter Quality Network ADHD Project Jeff Epstein PhD CQN ADHD National Expert/CQN Data Analyst The mehealth Portal and CQN.
Short-term efficacy of nicotine replacement therapy (NRT) for smoking cessation among adolescents and the role of compliance Charlotte Scherphof* Regina.
Vaccines for preventing influenza in healthy adults: a Cochrane review Clinical
Figure 1. Hazard ratios for progression-free survival analyzed with fixed effect model. Table 1: Relevant trials Table 2. Methodological quality Conclusions.
Thrombolysis for acute ischaemic stroke Clinical
2012 實證醫學系統課程 第一組 報告 吳敏誠、鍾宜倫、凌久惠 2012/08/07. Acyclovir for treating primary herpetic gingivostomatitis(Review) Cochrane Library 2008, Issue 4.
CONSORT 2010 Balakrishnan S, Pondicherry Institute of Medical Sciences.
Chronic pelvic pain Journal Club 17 th June 2011 Dr Claire Hoxley (GPST1) Dr Harpreet Rayar (GPST2)
Selenium supplementation for the primary prevention of cardiovascular disease: a Cochrane review Clinical
GRADE Grading of Recommendations Assessment, Development and Evaluation British Association of Dermatologists April 2014.
“Focusing on the Process” Jeff Schmidt MD.  Recommendation #1: Children ages 4-18 who present with academic underachievement, behavior problems or.
Randomized Controlled CTN Trial of OROS-MPH + CBT in Adolescents with ADHD and Substance Use Disorders Paula Riggs, M.D., Theresa Winhusen, PhD., Jeff.
Efficacy of the Elimination Diet in Children with ADHD: A Systematic Review Lola Achilova Pacific University School of Physician Assistant Studies, Hillsboro,
Effects of Uric acid- lowering therapy on renal outcomes: a systematic review and meta-analysis Nephrol Dial Transplant (2014) 29: Vaughan Washco.
Alcohol, Other Drugs, and Health: Current Evidence
Knowledge and Understanding
Foroutan N1,2, Muratov S1,2, Levine M1,2
مقدمة: الاطفال الذين يعانون من كثرة النشاط الحركى ليسوا باطفال مشاغبين، او عديمين التربية لكن هم اطفال عندهم مشكلة مرضية لها تاثير سيء على التطور النفسى.
Effekt og bivirkninger af methylphenidat behandling af børn og unge med ADHD- To Cochrane systematiske reviews Læge, Phd. Camilla Groth Cochrane gruppen.
ADHD & Autism.
Consultant Psychiatrist and Research Fellow, IoPPN.
Geir Smedslund, Ph.D.: Diakonhjemmet Hospital (DH)
1 Verstovsek S et al. Proc ASH 2012;Abstract Cervantes F et al.
The Research Question Background: Question:
Does cinnamon reduce fasting blood glucose in Type II diabetics?
Yoga treatment for chronic non-specific low back pain
Presentation transcript:

Webinar May 25th METHYLPHENIDATE FOR CHILDREN AND ADOLESCENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

Summary Background: Methylphenidate is the drug most often prescribed to treat children and adolescents with ADHD but, despite its widespread use, this is the first comprehensive systematic review of its benefits and harms. Objectives : To assess the beneficial and harmful effects of methylphenidate for children and adolescents with ADHD. Searches: All relevant databases until March 2015 and we checked for additional trials in the reference lists of relevant reviews and included trials. We contacted the pharmaceutical companies that manufacture methylphenidate to request published and unpublished data.

Summary cont. Number of included trials: 38 parallel-group trials and 147 cross-over trials Number of participants: Age: 3-21 years (mean age 9.7 years) Countries: United States, Canada, United Kingdom, Australia, Brazil, Isreal, Germany, Sweden, New Zealand, Norway, and the Netherlands Primary outcomes: ADHD symptoms and serious adverse events (life threatning) Secondary outcomes: Nonserious adverse events, general behaviour, and quality of life

Summary of findings  Primary outcomes. Methylphenidate may improve teacher- rated ADHD symptoms (standardised mean difference (SMD) , 95% confidence interval (CI) to -0.64; 19 trials, 1698 participants; very low-quality evidence).  Serious (e.g. life threatening) adverse events (risk ratio (RR) 0.98, 95% CI 0.44 to 2.22; nine trials, 1532 participants; very low-quality evidence). The Trial Sequential Analysis-adjusted intervention effect was 0.91 (95% CI 0.02 to 33.2).  Secondary outcomes. Non-serious adverse events: 29% increase in the overall risk of any non-serious adverse events (RR 1.29, 95% CI 1.10 to 1.51; 21 trials, 3132 participants; very low-quality evidence).

 Sleep problems: RR 1.60, 95% CI 1.15 to 2.23; 13 trials, 2416 participants); Decreased appetite: RR 3.66, 95% CI 2.56 to 5.23; 16 trials, 2962 participants).  Teacher-rated general behaviour seemed to improve with methylphenidate (SMD -0.87, 95% CI to -0.71; five trials, 668 participants; very low-quality evidence).  Parent-reported quality of life (SMD 0.61, 95% CI 0.42 to 0.80; 3 trials, 514 participants; very low-quality evidence

The quality of the evidence- Risk of bias Note: We consider all trials as potentially unblinded because methylphenidate is associated with easily recognizable adverse effects

GRADE assessments of outcomes  ADHD symptoms (downgraded two levels due to high risk of bias, one level for moderate statistical heterogeneity) Very low quality  Adverse events (downgraded two levels due to high risk of bias and downgraded one level due to imprecision) Very low quality  Non-serious adverse events ( downgraded two levels due to high risk of bias, one level for moderate statistical heterogeneity) Very low quality  General behavior (downgraded two levels due to high risk of bias, downgraded one level due to indirectness) Very low quality  Quality of life (downgraded two levels due to high risk of bias, downgraded one level due to indirectness) Very low quality

Conclusion  The results of meta-analyses suggest that methylphenidate may improve teacher-reported ADHD symptoms, teacher-reported general behaviour, and parent- reported quality of life among children and adolescents diagnosed with ADHD. However, the very low quality = Uncertain of the magnitude of the effects.  There is some evidence that methylphenidate is associated with increased risk of non-serious adverse events, such as sleep problems and decreased appetite, but no evidence that it increases risk of serious adverse events, however there was not enough data to assess this.  The median duration of drug treatment was less than 2 months and few trials had a treatment duration greater than 6 months.

The evidence base for methylphenidate treatment in children, adolescent and adults is flawed: The Epstein review.  GRADE assessment in the Epstein review: Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults:  Authors' conclusions:  Data from randomized controlled trials suggest that immediate-release methylphenidate is efficacious for treating adults with ADHD with symptoms of hyperactivity, impulsivity, and inattentiveness, and for improving their overall clinical condition.  In May 26 th 2016 this review will be withdrawn, due to subsequent criticism and unsatisfactory responses from the authors.

NICE guideline on ADHD in children and adolescents: meta-analysis: methylphenidate versus placebo.

Thank you for listening!